Article
Author(s):
Drs. Scott B. Shappell and Leonard S. Marks discuss clinical use of urine PCA3 mRNA testing for prostate cancer.
FDA awards orphan drug, rare pediatric disease designations to ABO-101 for PH1
Identifying Patients with Intermediate Risk in NMIBC
FDA Updates in Urology: January 2025
Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges
Urologic Cancer Facts and Updates for World Cancer Day 2025
Study points to increasing incidence of advanced prostate cancer in California